BridgeBio Pharma, Inc. (BBIO) vs Bio-Techne Corp (TECH)
BridgeBio Pharma, Inc. and Bio-Techne Corp are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $13.1B against $11.4B — 1.2× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Bio-Techne Corp trades at 62.1×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against −0.38%. Bio-Techne Corp has the higher net margin (15.0% vs −97.0%) and the higher return on invested capital (7.70% vs 0.00%). Across the 18 metrics below, Bio-Techne Corp leads on 12 and BridgeBio Pharma, Inc. on 6.
Valuation
Profitability
| Metric | BBIO | TECH | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.44% | 65.77% | 65.16% |
| Operating margin | (69.81%) | 20.73% | 0.00% |
| Net margin | (97.03%) | 14.97% | 0.00% |
| Free cash flow margin | (61.06%) | 21.66% | 0.00% |
| Return on equity | 32.31% | 9.03% | (57.72%) |
| Return on assets | (60.23%) | 7.07% | (49.22%) |
| Return on invested capital | 0.00% | 7.70% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack